PL1976559T6 - Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy - Google Patents

Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy

Info

Publication number
PL1976559T6
PL1976559T6 PL07734467T PL07734467T PL1976559T6 PL 1976559 T6 PL1976559 T6 PL 1976559T6 PL 07734467 T PL07734467 T PL 07734467T PL 07734467 T PL07734467 T PL 07734467T PL 1976559 T6 PL1976559 T6 PL 1976559T6
Authority
PL
Poland
Prior art keywords
matrix proteins
influenza vaccines
vaccines containing
containing hemagglutinin
hemagglutinin
Prior art date
Application number
PL07734467T
Other languages
English (en)
Other versions
PL1976559T3 (pl
Inventor
Michael Broeker
Holger Kost
Original Assignee
Novartis Influenza Vaccines Marburg Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0601733A external-priority patent/GB0601733D0/en
Priority claimed from GB0620175A external-priority patent/GB0620175D0/en
Application filed by Novartis Influenza Vaccines Marburg Gmbh filed Critical Novartis Influenza Vaccines Marburg Gmbh
Publication of PL1976559T3 publication Critical patent/PL1976559T3/pl
Publication of PL1976559T6 publication Critical patent/PL1976559T6/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07734467T 2006-01-27 2007-01-26 Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy PL1976559T6 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0601733A GB0601733D0 (en) 2006-01-27 2006-01-27 Vaccines
GB0620175A GB0620175D0 (en) 2006-10-11 2006-10-11 Vaccines
PCT/IB2007/001150 WO2007085969A2 (en) 2006-01-27 2007-01-26 Influenza vaccines containing hemagglutinin and matrix proteins
EP07734467.9A EP1976559B3 (en) 2006-01-27 2007-01-26 Influenza vaccines containing hemagglutinin and matrix proteins

Publications (2)

Publication Number Publication Date
PL1976559T3 PL1976559T3 (pl) 2017-07-31
PL1976559T6 true PL1976559T6 (pl) 2020-08-10

Family

ID=38309584

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11184022T PL2478916T3 (pl) 2006-01-27 2007-01-26 Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
PL07734467T PL1976559T6 (pl) 2006-01-27 2007-01-26 Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL11184022T PL2478916T3 (pl) 2006-01-27 2007-01-26 Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy

Country Status (16)

Country Link
US (2) US20110027314A1 (pl)
EP (3) EP1976559B3 (pl)
JP (3) JP6087041B2 (pl)
KR (2) KR20110110853A (pl)
AU (1) AU2007209019B2 (pl)
BR (2) BRPI0707300B8 (pl)
CA (1) CA2640248A1 (pl)
DK (2) DK2478916T3 (pl)
EA (1) EA015271B1 (pl)
ES (2) ES2796603T3 (pl)
FR (1) FR20C1046I1 (pl)
HU (1) HUE049580T2 (pl)
NZ (1) NZ570106A (pl)
PL (2) PL2478916T3 (pl)
PT (1) PT2478916T (pl)
WO (1) WO2007085969A2 (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0716992D0 (en) * 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
ES2555544T3 (es) 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
AU2007245192B2 (en) 2006-03-31 2012-04-12 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EP2268309B1 (en) 2008-03-18 2015-01-21 Novartis AG Improvements in preparation of influenza virus vaccine antigens
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
US8658180B2 (en) 2008-08-15 2014-02-25 Mark A. Miller Vaccines against influenza virus
PL222497B1 (pl) 2009-06-26 2016-08-31 Inst Biochemii I Biofizyki Pan Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania, kompozycja farmaceutyczna oraz zastosowanie wektorowej cząsteczki wirusopodobnej
JP2013507990A (ja) 2009-10-26 2013-03-07 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス
CA2780425C (en) * 2009-12-03 2014-02-04 Novartis Ag Hydrophilic filtration during manufacture of vaccine adjuvants
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
JP2014527799A (ja) 2011-08-26 2014-10-23 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
EP2768528A1 (en) 2011-10-20 2014-08-27 Novartis AG Adjuvanted influenza b virus vaccines for pediatric priming
ES2564138T3 (es) * 2011-12-12 2016-03-18 Novartis Ag Ensayo para Hemaglutinina del virus de la influenza
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
RU2523614C1 (ru) * 2013-04-09 2014-07-20 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Вакцина против гриппа и способ ее получения
WO2015006384A1 (en) * 2013-07-09 2015-01-15 Texas Tech University System Universal influenza vaccine
EP3022296B1 (en) 2013-07-15 2022-12-28 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
US10080792B2 (en) 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
KR102576962B1 (ko) * 2015-07-07 2023-09-11 세퀴러스 유케이 리미티드 인플루엔자 효능 검정
JP2019510481A (ja) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
JP2019064924A (ja) * 2016-02-24 2019-04-25 Ａｇｃ株式会社 インフルエンザワクチン
EP3700562A1 (en) 2017-10-25 2020-09-02 Wisconsin Alumni Research Foundation (WARF) Recombinant influenza viruses with stabilized ha for replication in eggs
SG11202003793WA (en) 2017-10-30 2020-05-28 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
EP3730620A4 (en) 2017-12-21 2022-01-05 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
JP7783047B2 (ja) 2018-08-07 2025-12-09 ウィスコンシン アルムニ リサーチ ファンデイション 組換えの生物学的に封じ込められたフィロウイルスワクチン
EP3840780A1 (en) 2018-08-20 2021-06-30 Wisconsin Alumni Research Foundation Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4060082A (en) 1976-08-16 1977-11-29 Mpl, Inc. Dual-ingredient medication dispenser
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
AU631377B2 (en) 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
US5741493A (en) * 1991-01-24 1998-04-21 Pasteur Merieux Serums Et Vaccins Vaccine composition against influenza, with synergic effects, containing influenza virus core as an additive
UA32546C2 (uk) 1991-03-01 2001-02-15 Міннесота Майнінг Енд Мен'Юфекчурінг Компані 1,2-заміщені 1н-імідазо[4,5-с]хінолін-4-аміни, проміжні сполуки для їх синтезу, антивірусна фармацевтична композиція, спосіб лікування інфікованих ссавців, спосіб індукування біосинтезу інтерферону у ссавців, спосіб уповільнення росту бластом
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JPH0614756Y2 (ja) 1991-06-26 1994-04-20 株式会社アルテ 組み立て式の２室式容器兼用注射器
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
MY111880A (en) 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
ES2109685T5 (es) 1993-03-23 2005-09-01 Smithkline Beecham Biologicals S.A. Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado.
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
ATE195735T1 (de) 1993-07-15 2000-09-15 Minnesota Mining & Mfg Imidazo (4,5-c)pyridin-4-amine
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5496284A (en) 1994-09-27 1996-03-05 Waldenburg; Ottfried Dual-chamber syringe & method
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
GB9503863D0 (en) 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
WO1998001174A1 (fr) 1996-07-05 1998-01-15 Debiotech S.A. Seringue a chambre double permettant le melange de deux produits avant leur injection
EP2172216A3 (en) 1997-03-10 2010-11-24 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
AU7126998A (en) 1997-04-16 1998-11-11 Connaught Laboratories Inc. Anti-influenza compositions supplemented with neuraminidase
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US5971953A (en) 1998-01-09 1999-10-26 Bachynsky; Nicholas Dual chamber syringe apparatus
WO1999017820A1 (en) 1997-10-03 1999-04-15 Texas Pharmaceuticals, Inc. Improved dual chamber syringe apparatus
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
HK1039072A1 (zh) 1998-05-07 2002-04-12 科里克萨有限公司 佐剂组合物及其使用方法
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE19835749C1 (de) 1998-08-07 2000-02-03 Dieter Perthes Fertig-Spritze für nicht-stabile Arzneimittel
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
DK1126876T3 (da) 1998-10-16 2007-07-02 Glaxosmithkline Biolog Sa Adjuvanssystemer og vacciner
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
DE60013773T2 (de) 1999-02-03 2005-11-10 Biosante Pharmaceuticals, Inc. Methoden zur Herstellung von therapeutischen Kalziumphosphat Partikeln
EP1165140B1 (en) 1999-03-26 2004-08-04 Vical Incorporated Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines
CA2365526C (en) 1999-04-06 2016-07-05 Wisconsin Alumni Research Foundation Recombinant influenza viruses for vaccines and gene therapy
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
AU5998400A (en) 1999-07-14 2001-01-30 Mount Sinai School Of Medicine Of The City University Of New York, The In vitro reconstitution of segmented negative-strand rna viruses
EP1221971A2 (en) 1999-09-24 2002-07-17 SmithKline Beecham Biologics SA Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
CA2383110A1 (en) 1999-09-24 2001-03-29 Veronique Henderickx Adjuvant comprising a polyoxyethylene alkyl ether or ester and at least one non-ionic surfactant
WO2001021151A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Intranasal influenza virus vaccine
UA77152C2 (en) 1999-09-25 2006-11-15 Method for stimulation of immune response using nucleic acid-containing immunostimulating compositions, method for treatment of cancer and method for treatment or prophylaxis of allergy or asthma
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
JP4698112B2 (ja) 2000-03-03 2011-06-08 一般財団法人化学及血清療法研究所 無血清培養かつ浮遊培養可能な細胞及び当該細胞を用いたワクチン用ウイルスの製造法
AU2001259211B2 (en) * 2000-04-28 2006-07-13 St. Jude Children's Research Hospital DNA transfection system for the generation of infectious influenza virus
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
JP4341949B2 (ja) 2000-09-01 2009-10-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アザ複素環式誘導体およびその治療的使用
PL211125B1 (pl) 2000-09-11 2012-04-30 Novartis Vaccines & Diagnostic Pochodne chinolinonu jako inhibitory kinazy tyrozynowej, kompozycje je zawierające i ich zastosowanie
CA2423487C (en) 2000-09-26 2015-12-15 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
EP2281573A3 (en) 2001-02-23 2011-12-07 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
EP1361889A1 (en) 2001-02-23 2003-11-19 GlaxoSmithKline Biologicals S.A. Novel vaccine
MXPA03008154A (es) 2001-03-09 2004-11-12 Id Biomedical Corp Quebec Novedoso adyuvante de vacuna de proteosoma-liposacarido.
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US6592136B2 (en) 2001-07-02 2003-07-15 Fox Factory, Inc. Bicycle fork cartridge assembly
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
IL162137A0 (en) 2001-11-27 2005-11-20 Anadys Pharmaceuticals Inc D-ribofuranosylthiazolo -3-Ä4,5-dÜpyridimine nucl eosides and uses thereof
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
ATE447404T1 (de) 2002-03-29 2009-11-15 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
AU2003233519A1 (en) 2002-05-29 2003-12-19 3M Innovative Properties Company Process for imidazo(4,5-c)pyridin-4-amines
EP1551228B1 (en) 2002-06-13 2012-10-03 New York University Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
CN1688573A (zh) 2002-08-23 2005-10-26 希龙公司 糖原合成酶激酶3的吡咯基抑制剂
WO2004060308A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
WO2004064759A2 (en) 2003-01-21 2004-08-05 Chiron Corporation Use of tryptanthrin compounds for immune potentiation
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
RU2236257C1 (ru) 2003-09-15 2004-09-20 Косяков Константин Сергеевич Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
EP1722815A1 (en) * 2004-03-09 2006-11-22 Chiron Corporation Influenza virus vaccines
CN1933862A (zh) 2004-03-23 2007-03-21 尼普洛株式会社 预充式注射器
AU2005235080A1 (en) 2004-03-31 2005-11-03 New York University Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
EP1742659B1 (en) 2004-04-05 2013-03-13 Pah Usa 15 Llc Microfluidized oil-in-water emulsions and vaccine compositions
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
NZ551640A (en) 2004-05-20 2010-05-28 Id Biomedical Corp Process for the production of an influenza vaccine
JP2008504292A (ja) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 免疫増強用の化合物
JP2008512443A (ja) 2004-09-09 2008-04-24 カイロン ベーリング ゲーエムベーハー アンド カンパニー インフルエンザワクチンに関連する潜在的医原性リスクの減少
EP1831353B1 (en) 2004-12-23 2012-02-29 MedImmune, LLC Non-tumorigenic mdck cell line for propagating viruses
KR101272487B1 (ko) 2004-12-24 2013-06-07 에라스무스 유니버시티 메디컬 센터 로테르담 인플루엔자 바이러스의 구제
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
EP1945250A4 (en) * 2005-08-16 2010-05-19 Hawaii Biotech Inc RECOMBINANT SUBUNIT VACCINE AGAINST INFLUENZA
NZ567817A (en) 2005-11-01 2012-01-12 Novartis Vaccines & Diagnostic Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
ATE552846T1 (de) * 2005-12-06 2012-04-15 Yeda Res & Dev Verbesserter grippeimpfstoff

Also Published As

Publication number Publication date
DK1976559T6 (da) 2020-04-06
EP2478916B1 (en) 2020-04-01
JP6275229B2 (ja) 2018-02-07
NZ570106A (en) 2012-04-27
US20110027314A1 (en) 2011-02-03
ES2619160T7 (es) 2020-07-29
KR20110110853A (ko) 2011-10-07
DK1976559T3 (en) 2017-02-27
EP1976559B1 (en) 2017-01-04
WO2007085969A2 (en) 2007-08-02
JP2009524639A (ja) 2009-07-02
FR20C1046I1 (fr) 2020-11-27
BRPI0707300A8 (pt) 2017-08-22
ES2796603T3 (es) 2020-11-27
BRPI0707300B8 (pt) 2021-05-25
AU2007209019A1 (en) 2007-08-02
WO2007085969A3 (en) 2007-12-27
CA2640248A1 (en) 2007-08-02
BRPI0707300A2 (pt) 2011-05-03
JP6087041B2 (ja) 2017-03-08
BR122019013216B1 (pt) 2020-05-05
EP2478916A1 (en) 2012-07-25
ES2619160T3 (es) 2017-06-23
JP2017031225A (ja) 2017-02-09
EA015271B1 (ru) 2011-06-30
KR20080089663A (ko) 2008-10-07
US20160158340A1 (en) 2016-06-09
PL2478916T3 (pl) 2020-11-16
PL1976559T3 (pl) 2017-07-31
BR122019013216B8 (pt) 2021-07-27
EP3753574A1 (en) 2020-12-23
EP1976559B3 (en) 2020-02-19
EP1976559A2 (en) 2008-10-08
PT2478916T (pt) 2020-07-03
DK2478916T3 (da) 2020-06-15
EA200801756A1 (ru) 2009-02-27
AU2007209019B2 (en) 2012-11-29
HUE049580T2 (hu) 2020-09-28
BRPI0707300B1 (pt) 2019-12-10
JP2014205712A (ja) 2014-10-30

Similar Documents

Publication Publication Date Title
PL1976559T3 (pl) Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
IL196024A0 (en) Influenza vaccine
EP1771552A4 (en) INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS
PL2185191T3 (pl) Szczepionki przeciwko grypie o małej zawartości dodatków
EP2091960A4 (en) PEPTIDE VACCINE AGAINST INFLUENZA VIRUS
SI2091560T1 (sl) Cepiva proti ptičji gripi za mačke
IL213189A0 (en) Recombinant avian influenza vaccine and uses thereof
EP1948227A4 (en) COMBINATORY ANTIGEN VACCINE AGAINST FLU
ZA200809056B (en) Influenza virus vaccine
ZA200905952B (en) Lyophilized preparation comprising influenza vaccine,and method for preparation thereof
EP1998814A4 (en) NEW VACCINES AGAINST INFLUENZA M2
SI2043682T1 (sl) Influenčno cepivo
PT1942933E (pt) Vacinas contra a gripe canina
EP2097103A4 (en) VACCINE FORMULATIONS AGAINST INFLUENZA
ZA200900062B (en) Influenza vaccine
GB0522601D0 (en) Adjuvanted influenza vaccines and kits
GB0618195D0 (en) Influenza vaccine
GB0619090D0 (en) Influenza vaccine
GB0623218D0 (en) Influenza vaccine
GB0623865D0 (en) Influenza vaccine
GB0625453D0 (en) Influenza vaccine
HK1132654A (en) Influenza hemagglutinin and neuraminidase variants
IL191977A0 (en) Improved influenza vaccine
HK1102763A (en) Vaccines for the rapid response to pandemic avian influenza
GB0605761D0 (en) Anti-inflammatory proteins and improved vaccines